OCGN, or Ocugen Inc., is a biopharmaceutical company that is primarily focused on developing treatments for various eye diseases. The company is listed on the NASDAQ stock exchange and has garnered significant attention from investors on the popular social media platform, Stocktwits.

The company’s primary product in development is a potential gene therapy treatment for the rare eye disease, inherited retinal disorders (IRDs). Ocugen is also developing a COVID-19 vaccine in partnership with Bharat Biotech, which has generated significant interest in the wake of the ongoing pandemic.

Investors on Stocktwits have been closely following the progress of Ocugen’s clinical trials and the company’s partnerships with other pharmaceutical companies. Many are optimistic about the potential of Ocugen’s treatments and have been buying shares in the company as a result.

However, it is important to note that investing in biotech companies like Ocugen can be risky due to the unpredictable nature of drug development and regulatory approval processes. As with any investment, investors should do their own research and carefully consider the risks before making any decisions.

In conclusion, Ocugen is a biopharmaceutical company that is actively developing treatments for various eye diseases and a COVID-19 vaccine. The company has garnered significant attention from investors on Stocktwits, but caution should be exercised when investing in such companies.